From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Do I need to make an apology to dividend muncher favourite GlaxoSmithKline?

By Chris Bailey | Wednesday 19 December 2018


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Much has been said or written about GlaxoSmithKline (GSK) during 2018 and my most recent contribution back in July suggested that a divisional split-up was a spoof. Well today's announcement that Glaxo has formed a joint venture vehicle with US pharma behemoth Pfizer for their respective consumer health arms (with ownership split 68%/32% in favour of Glaxo) appears at face value like a step in the right direction for under pressure CEO Emma Walmsley and team…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 12:52:16